# Fortis Healthcare (NSE: FORTIS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/FORTIS · Pivot · prices to 22 Oct 2026

Fortis Healthcare (NSE: FORTIS) closed at ₹720.15 on 22 Oct 2026, down 0.67% on the day. With a market capitalisation of ₹54,859 Cr, it ranks 184th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.

At its last close the stock traded at 52.3× trailing earnings, against a return on equity of 10.5% in FY26. Over the past year the share price has fallen 33.5%. Its 52-week range is ₹710.80 (22 Oct 2026) to ₹1,104.00 (23 Oct 2025); the last close is 34.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹2,545 Cr (+17.5% year on year) and net profit ₹268 Cr (+1.7%), on a consolidated basis. Promoters held 31.17% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹720.15 |
| Market cap | ₹54,859 Cr |
| P/E (trailing) | 52.3 |
| ROE | 10.5% (FY26) |
| ROCE | 12.2% (FY26) |
| Debt to equity | 0.29 |
| 52-week high | ₹1,104.00 (23 Oct 2025) |
| 52-week low | ₹710.80 (22 Oct 2026) |
| 1-year return | −33.5% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹2,545 Cr | +17.5% | ₹268 Cr | +1.7% | ₹3.53 |
| Q4 FY26 | ₹2,365 Cr | +17.8% | ₹265 Cr | +44.5% | ₹3.52 |
| Q3 FY26 | ₹2,265 Cr | +17.5% | ₹194 Cr | −23.1% | ₹2.57 |
| Q2 FY26 | ₹2,331 Cr | +17.3% | ₹325 Cr | +72.2% | ₹4.26 |
| Q1 FY26 | ₹2,167 Cr | +16.6% | ₹264 Cr | +52.2% | ₹3.45 |
| Q4 FY25 | ₹2,007 Cr | +12.4% | ₹183 Cr | −7.8% | ₹2.44 |
| Q3 FY25 | ₹1,928 Cr | +14.8% | ₹252 Cr | +94.5% | ₹3.28 |
| Q2 FY25 | ₹1,988 Cr | +12.3% | ₹189 Cr | +3.4% | ₹2.34 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹7,783 Cr | ₹798 Cr |
| FY24 | ₹6,893 Cr | ₹636 Cr |
| FY23 | ₹6,298 Cr | ₹611 Cr |
| FY22 | ₹5,718 Cr | ₹766 Cr |
| FY21 | ₹4,030 Cr | −₹104 Cr |
| FY20 | ₹4,632 Cr | ₹79 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 31.17%
- Foreign institutions: 25.20%
- Domestic institutions: 32.23%
- Non-institutions: 11.40%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Alkem Laboratories](https://app.pivotnow.in/stock/ALKEM) | ₹4,972.00 | ₹59,962 Cr | 25.8 | 16.6% |
| [Aster DM Health](https://app.pivotnow.in/stock/ASTERDM) | ₹647.20 | ₹56,672 Cr | 101.1 | 8.5% |
| [Abbott India](https://app.pivotnow.in/stock/ABBOTINDIA) | ₹25,445.00 | ₹53,888 Cr | 34.8 | 33.4% |
| [Biocon](https://app.pivotnow.in/stock/BIOCON) | ₹332.85 | ₹53,829 Cr | 117.6 | 1.1% |
| [IPCA Laboratories](https://app.pivotnow.in/stock/IPCALAB) | ₹1,932.90 | ₹48,683 Cr | 43 | 14.2% |
| [Gland Pharma](https://app.pivotnow.in/stock/GLAND) | ₹2,910.60 | ₹47,020 Cr | 46.7 | 9.9% |

## Questions and answers

### What is the share price of Fortis Healthcare today?

Fortis Healthcare (NSE: FORTIS) last closed at ₹720.15 on 22 Oct 2026. Its 52-week high is ₹1,104.00 and its 52-week low is ₹710.80.

### What is the market cap of Fortis Healthcare?

Fortis Healthcare's market capitalisation is ₹54,859 Cr (₹54,859 Cr) at the 22 Oct 2026 close, ranking 184th among the NSE companies Pivot tracks.

### What is the P/E ratio of Fortis Healthcare?

Fortis Healthcare trades at a trailing P/E of 52.3. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.7.

### What is the ROE and ROCE of Fortis Healthcare?

Return on equity was 10.5% in FY26 and return on capital employed was 12.2% in FY26 (consolidated figures).

### Is Fortis Healthcare a debt-free company?

No. Fortis Healthcare's debt-to-equity ratio was 0.29 in FY26, with total debt of ₹2,401 Cr.

### What were Fortis Healthcare's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Fortis Healthcare reported revenue of ₹2,545 Cr, +17.5% year on year, and net profit of ₹268 Cr, +1.7% year on year.

### How has Fortis Healthcare stock performed over the last year?

Fortis Healthcare's share price has fallen 33.5% over the past year, −24.2% over three months and −19.6% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Fortis Healthcare?

As of 30 Jun 2026: promoters 31.17%, foreign institutions 25.20%, domestic institutions 32.23%, non-institutions 11.40%.

### Who are Fortis Healthcare's competitors?

The listed Pharma & Healthcare companies closest to Fortis Healthcare by market cap are Alkem Laboratories, Aster DM Health, Abbott India, Biocon, IPCA Laboratories and Gland Pharma.

### Is Fortis Healthcare a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Fortis Healthcare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FORTIS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.